Literature DB >> 27151995

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

Sanne J de Haart1, Lisa Holthof2, Willy A Noort2, Monique C Minnema3, Maarten E Emmelot3, Tineke Aarts-Riemens1, Parul Doshi4, Kate Sasser4, Huipin Yuan5, Joost de Bruijn5, Anton C M Martens2, Niels W C J van de Donk2, Henk M Lokhorst2, Richard W J Groen2, Tuna Mutis6.   

Abstract

Entities:  

Keywords:  abrogation; bone marrow stromal cell; cell lysis; deratumumab; multiple myeloma; sepantronium bromide

Mesh：

Substances：

Year:  2016        PMID： 27151995      PMCID： PMC4967585          DOI： 10.3324/haematol.2015.139667

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   11.047


× No keyword cloud information.
  16 in total

1.  Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.

Authors:  Inger S Nijhof; Richard W J Groen; Willy A Noort; Berris van Kessel; Regina de Jong-Korlaar; Joost Bakker; Jeroen J L van Bueren; Paul W H I Parren; Henk M Lokhorst; Niels W C J van de Donk; Anton C M Martens; Tuna Mutis
Journal:  Clin Cancer Res       Date:  2014-11-14       Impact factor: 12.531

2.  Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells.

Authors:  T Lwin; L A Hazlehurst; Z Li; S Dessureault; E Sotomayor; L C Moscinski; W S Dalton; J Tao
Journal:  Leukemia       Date:  2007-05-03       Impact factor: 11.528

Review 3.  Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.

Authors:  Alain C Mita; Monica M Mita; Steffan T Nawrocki; Francis J Giles
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 4.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

5.  Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery.

Authors:  Massimo Giuliani; Noufissa Oudrhiri; Zaeem M Noman; Amelia Vernochet; Salem Chouaib; Bruno Azzarone; Antoine Durrbach; Annelise Bennaceur-Griscelli
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

6.  Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation.

Authors:  J S Damiano; L A Hazlehurst; W S Dalton
Journal:  Leukemia       Date:  2001-08       Impact factor: 11.528

7.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

8.  Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

Authors:  Sanne J de Haart; Niels W C J van de Donk; Monique C Minnema; Julie H Huang; Tineke Aarts-Riemens; Niels Bovenschen; Huipin Yuan; Richard W J Groen; Douglas W McMillin; Jana Jakubikova; Henk M Lokhorst; Anton C Martens; Constantine S Mitsiades; Tuna Mutis
Journal:  Clin Cancer Res       Date:  2013-09-04       Impact factor: 13.801

9.  Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.

Authors:  Aya Kita; Keisuke Mitsuoka; Naoki Kaneko; Mari Nakata; Kentaro Yamanaka; Makoto Jitsuoka; Sosuke Miyoshi; Akihiro Noda; Masamichi Mori; Takahito Nakahara; Masao Sasamata
Journal:  J Pharmacol Exp Ther       Date:  2012-07-11       Impact factor: 4.402

10.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Authors:  Takahito Nakahara; Aya Kita; Kentaro Yamanaka; Masamichi Mori; Nobuaki Amino; Masahiro Takeuchi; Fumiko Tominaga; Shinji Hatakeyama; Isao Kinoyama; Akira Matsuhisa; Masafumi Kudoh; Masao Sasamata
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 13.312
View more
  14 in total

1.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

2.  Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.

Authors:  Michelle L Miller; Olivera J Finn
Journal:  Methods Enzymol       Date:  2019-08-12       Impact factor: 1.600

3.  The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.

Authors:  Shyril O'Steen; Melissa L Comstock; Johnnie J Orozco; Donald K Hamlin; D Scott Wilbur; Jon C Jones; Aimee Kenoyer; Margaret E Nartea; Yukang Lin; Brian W Miller; Theodore A Gooley; Sherilyn A Tuazon; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; Oliver W Press; Damian J Green
Journal:  Blood       Date:  2019-10-10       Impact factor: 22.113

4.  Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.

Authors:  Christie P M Verkleij; Marloes E C Broekmans; Mark van Duin; Kristine A Frerichs; Rowan Kuiper; A Vera de Jonge; Martin Kaiser; Gareth Morgan; Amy Axel; Rengasamy Boominathan; Jocelyn Sendecki; Amy Wong; Raluca I Verona; Pieter Sonneveld; Sonja Zweegman; Homer C Adams; Tuna Mutis; Niels W C J van de Donk
Journal:  Blood Adv       Date:  2021-04-27

Review 5.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

Review 6.  Immunotherapy in myeloma: how far have we come?

Authors:  Laurens E Franssen; Tuna Mutis; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Ther Adv Hematol       Date:  2019-01-18

7.  Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK.

Authors:  David Danielpour; Zhaofeng Gao; Patrick M Zmina; Eswar Shankar; Benjamin C Shultes; Raul Jobava; Scott M Welford; Maria Hatzoglou
Journal:  Sci Rep       Date:  2019-08-08       Impact factor: 4.996

Review 8.  Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance.

Authors:  Lisa C Holthof; Tuna Mutis
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

9.  CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.

Authors:  Arwen Stikvoort; Jort van der Schans; Subhashis Sarkar; Renée Poels; Ruud Ruiter; Jyoti Naik; Huipin Yuan; Joost D de Bruijn; Niels W C J van de Donk; Sonja Zweegman; Maria Themeli; Richard Groen; Michael O'Dwyer; Tuna Mutis
Journal:  Hemasphere       Date:  2021-06-12

Review 10.  CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

Authors:  Niels W C J van de Donk; Saad Z Usmani
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.